Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 1. Trial profile. (A) Part A and (B) part B

Published byKaren Nørgaard Modified over 5 years ago

Similar presentations

Presentation on theme: "Figure 1. Trial profile. (A) Part A and (B) part B"— Presentation transcript:

1 Figure 1. Trial profile. (A) Part A and (B) part B
Figure 1. Trial profile. (A) Part A and (B) part B. Screen failure was largely attributable to patients with no PIK3CA ... Figure 1. Trial profile. (A) Part A and (B) part B. Screen failure was largely attributable to patients with no PIK3CA mutations identified after 25 September 2015 when enrolment of PIK3CA– patients had ceased because the target number of PIK3CA– patients had been reached. All randomised patients received paclitaxel and all but one, randomised to the placebo group, received either capivasertib or matching placebo as assigned per the randomisation schema. b.i.d., twice daily; PIK3CA, phosphoinositide-3-kinase, catalytic, alpha polypeptide. Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) Published by Oxford University Press on behalf of the European Society for Medical Oncology.This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact Ann Oncol, Volume 30, Issue 5, 12 March 2019, Pages 774–780, The content of this slide may be subject to copyright: please see the slide notes for details.

2 Figure 2. Progression-free survival (PFS) in part B
Figure 2. Progression-free survival (PFS) in part B. (A) PFS in the overall population of part B. (B) PFS in the ... Figure 2. Progression-free survival (PFS) in part B. (A) PFS in the overall population of part B. (B) PFS in the PIK3CA+ sub-population of part B. ●, a censored observation, assessed using RECIST v1.1 criteria. HR, hazard ratio; PFS, progression-free survival; PIK3CA, phosphoinositide-3-kinase, catalytic, alpha polypeptide; RECIST, Response Evaluation Criteria In Solid Tumours Version 1.1. Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) Published by Oxford University Press on behalf of the European Society for Medical Oncology.This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact Ann Oncol, Volume 30, Issue 5, 12 March 2019, Pages 774–780, The content of this slide may be subject to copyright: please see the slide notes for details.

Download ppt "Figure 1. Trial profile. (A) Part A and (B) part B"

Similar presentations

Table 1 Patient characteristics of attendees of the influenza vaccination, irrespective of AF status From: Yield of screening for atrial fibrillation in.

Table 1 Patient characteristics of attendees of the influenza vaccination, irrespective of AF status From: Yield of screening for atrial fibrillation in.
Figure 1 Proportion of criteria chosen (as percentages, grouped into issues). From: Developing national obesity policy in middle-income countries: a case.

Figure 1 Proportion of criteria chosen (as percentages, grouped into issues). From: Developing national obesity policy in middle-income countries: a case.
From: Learning by Working in Big Cities

From: Learning by Working in Big Cities
Fig. 1 Nodes in a conceptual knowledge graph

Fig. 1 Nodes in a conceptual knowledge graph
Figure 1: Pneumomediastinum and subcutaneous emphysema as indicated by the arrows. From: Pneumomediastinum and subcutaneous emphysema after successful.

Figure 1: Pneumomediastinum and subcutaneous emphysema as indicated by the arrows. From: Pneumomediastinum and subcutaneous emphysema after successful.
From: Detection of Bacteriuria by Canine Olfaction

From: Detection of Bacteriuria by Canine Olfaction
Figure 1. The flow chart illustrates the construction process of anti-CRISPRdb, and the information that users can obtain from anti-CRISPRdb. From: Anti-CRISPRdb:

Figure 1. The flow chart illustrates the construction process of anti-CRISPRdb, and the information that users can obtain from anti-CRISPRdb. From: Anti-CRISPRdb:
Abstract From: Lung transplantation after ex vivo lung perfusion in two Scandinavian centres Eur J Cardiothorac Surg. Published online October 29, 2018.

Abstract From: Lung transplantation after ex vivo lung perfusion in two Scandinavian centres Eur J Cardiothorac Surg. Published online October 29, 2018.
Figure 1: Necrobiosis lipoidica: Yellow-brown skin lesions with indurated borders located on both lower legs. Figure 1: Necrobiosis lipoidica: Yellow-brown.

Figure 1: Necrobiosis lipoidica: Yellow-brown skin lesions with indurated borders located on both lower legs. Figure 1: Necrobiosis lipoidica: Yellow-brown.
Figure 1. Circular taxonomy tree based on the species that were sequenced in our study. Unless provided in the caption above, the following copyright applies.

Figure 1. Circular taxonomy tree based on the species that were sequenced in our study. Unless provided in the caption above, the following copyright applies.
ADAb: anti-drug antibody.

ADAb: anti-drug antibody.
FIGURE 1 Kidney biopsies of Patients 1 and 2

FIGURE 1 Kidney biopsies of Patients 1 and 2
Figure 1 Hazard ratios as a function of annual mean PM2

Figure 1 Hazard ratios as a function of annual mean PM2
Figure 1 Schematic representation of the extreme SVD design in the 3C-Dijon study. Unless provided in the caption above, the following copyright applies.

Figure 1 Schematic representation of the extreme SVD design in the 3C-Dijon study. Unless provided in the caption above, the following copyright applies.
Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.
Figure 1: Axial T2 W images of penis showed a well-defined septated area of 2 cm in the posterior aspect of ... Figure 1: Axial T2 W images.

Figure 1: Axial T2 W images of penis showed a well-defined septated area of 2 cm in the posterior aspect of ... Figure 1: Axial T2 W images.
FIGURE 1 Histological diagnoses divided into 8-year time frames (n = 1208). Unless provided in the caption above, the following copyright applies to the.

FIGURE 1 Histological diagnoses divided into 8-year time frames (n = 1208). Unless provided in the caption above, the following copyright applies to the.
FIGURE 1 The effect of daprodustat on hemoglobin (Hgb) levels

FIGURE 1 The effect of daprodustat on hemoglobin (Hgb) levels
FIGURE 2 Responses to the question: regarding vasoactive drugs, does your centre use the following frequently, rarely ... FIGURE 2 Responses to the question:

FIGURE 2 Responses to the question: regarding vasoactive drugs, does your centre use the following frequently, rarely ... FIGURE 2 Responses to the question:
FIGURE 1 Maternal (A) urinary aldosterone; (B) plasma active renin; (C) urinary AGT concentrations; and (D) plasma AGT ... FIGURE 1 Maternal (A) urinary.

FIGURE 1 Maternal (A) urinary aldosterone; (B) plasma active renin; (C) urinary AGT concentrations; and (D) plasma AGT ... FIGURE 1 Maternal (A) urinary.

Similar presentations

Ads by Google